Abstract
Objective To investigate the features of patients with cyclic citrullinated peptide (CCP) antibodies in primary Sjogren's syndrome (pSS) with the retrospective method. Methods Seventy eight pSS patients were studied. Enzyme-linked immunosorbent assay (ELISA) indirect immunofluorescence was used to measure anti-CCP antibodies. The patients with and without anti-CCP antibodies were correspondingly classified as autoantibody-positive and negative pSS groups. Clinical and laboratory features were compared between autoantibody-negative and positive group. Results ⑴ Seven (9.0%) of pSS patients had positive anti-CCP antibody. No significant difference was found in sex, ages, and disease course between autoantibody-nagative and positive pSS patients. ⑵ The anti-CCP-positive pSS was associated with the rates of decayed tooth, fatigue, dry mouth, dry eyes, and tender of joint (P 0.05). ⑶From serologic characteristics aspects, the anti-CCP-positive patients showed higher level of tender of joint than the anti-CCP-negative patients. No significant difference was found in white blood cell (WBC), hemoglobin (HGB), platelet (PLT), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), immunoglobulin A (IgA), IgG, IgM, and rheumatoid factor (RF) between two groups (P>0.05). Conclusions The anti-CCP-positive patients were 9% of pSS patients, and were more likely to occur tender of joint with higher level of tender of joint. Key words: Sjogren's syndrome/ME/DI; Peptides, cyclic/ME; Autoantibodies/ME
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.